90830-11-8

Usage

Uses

Used in Pharmaceutical Research:
2-Methylimidazo[1,2-a]pyrimidine-3-carboxylic acid, 97+% is used as a key intermediate in pharmaceutical research for the synthesis of novel drug candidates. Its unique chemical structure and functional group contribute to the development of compounds with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Methylimidazo[1,2-a]pyrimidine-3-carboxylic acid, 97+% is employed as a versatile building block for the creation of complex organic molecules. Its reactivity and structural features facilitate the formation of diverse chemical entities for various applications.
Used in Bioactive Compounds Development:
2-Methylimidazo[1,2-a]pyrimidine-3-carboxylic acid, 97+% is utilized in the development of bioactive compounds, leveraging its potential pharmacological properties. It serves as a foundation for designing and synthesizing molecules with specific biological activities, targeting various therapeutic areas.
Used in Research and Industrial Applications:
Due to its high purity of 97% or greater, 2-Methylimidazo[1,2-a]pyrimidine-3-carboxylic acid is suitable for use in research and industrial applications where accurate chemical composition and consistent results are paramount. Its purity ensures reliable outcomes in experiments and manufacturing processes.

InChI:InChI=1/C8H7N3O2/c1-5-6(7(12)13)11-4-2-3-9-8(11)10-5/h2-4H,1H3,(H,12,13)

Upstream product

• 62772-70-7 ethyl 2-methylimidazo[1,2-a]pyrimidine-3-carboxylate 

Relevant academic research and scientific papers

Structural modification of zolpidem led to potent antimicrobial activity in imidazo[1,2-: A] pyridine/pyrimidine-1,2,3-triazoles

Ambien (zolpidem), an imidazo[1,2-a]pyridine derivative, is a commercial drug to treat insomnia which also possesses antitubercular activity against Mycobacterium tuberculosis H37Rv. In this paper, we describe the synthesis of three diverse lead series of imidazo[1,2-a]pyridine/pyrimidine-1,2,3-triazoles (IPTs) which are designed by specific structural modifications of zolpidem. Most of the IPTs exhibited remarkable in vitro antitubercular activity with an MIC of 1.56 μg mL-1, which is two-fold higher than the MIC of zolpidem. Further, the synthesized IPTs displayed moderate inhibitory activity against several bacterial and fungal strains as well, and also showed an acceptable safety profile as verified through in vitro cytotoxicity assessment against Vero cells. In addition, the potent IPTs exhibited promising binding interactions within the active site of the InhA enzyme. An interesting correlation between the in vitro inhibitory activity and the binding mode was observed: most of the potent molecules (MIC = 1.56 μg mL-1) interact through a H-bond with the Tyr 158 residue of the target enzyme. These efforts toward the structural modification of zolpidem could be helpful for further optimization of the IPT core to develop new anti-TB drugs.

Research on heterocyclic compounds - Part XXXIX. 2-Methylimidazo[1,2-a]pyrimidine-3-carboxylic derivatives: Synthesis and antiinflammatory activity

The synthesis of a group of 2-methylimidazo[1,2-a]pyrimidine-3-carboxylic esters, acids and amides is described. The structures of new compounds are supported by 1H and 13C NMR spectra. These compounds were tested in vivo for their antiinflammatory analgesic and ulcerogenic activity. Eight new compounds out of fifteen showed remarkable dose-dependent antiinflammatory action in die carrageenan rat paw edema (1/2-1/3 x indomethacin) but weak analgesic activity in the acetic acid writhing test together with negligible ulcerogenic action. The new compounds were found to be lacking in inhibitory activity on cyclooxygenase in vitro.